Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Gupta, Digant ^a   Lis, Christopher G ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; MUCIN 1; PACLITAXEL; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW;

EID: 77953406093     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-13     Document Type: Review

References (80)

1. Patterns and progress in ovarian cancer over 14 years. JK Chan MK Cheung A Husain NN Teng D West AS Whittemore JS Berek K Osann, Obstet Gynecol 2006 108 521 528 16946210
2. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. P Hartge AS Whittemore J Itnyre L McGowan D Cramer, Obstet Gynecol 1994 84 760 764 7936508
3. Ovarian cancer incidence in the United States, 1992-1999. JT Quirk N Natarajan, Gynecol Oncol 2005 97 519 523 10.1016/j.ygyno.2005.02.007 15863154
4. Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period 1978-2002. CG Hannibal R Cortes G Engholm SK Kjaer, Acta Obstet Gynecol Scand 2008 1 9
5. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. A van Dalen J Favier A Burges U Hasholzner HW de Bruijn D Dobler-Girdziunaite VH Dombi D Fink M Giai P McGing A Harlozinska C Kainz J Markowska R Molina C Sturgeon A Bowman R Einarsson, Gynecol Oncol 2000 79 444 450 10.1006/gyno.2000.5982 11104617
6. Status of tumor markers in ovarian cancer screening. RC Bast Jr, J Clin Oncol 2003 21 200s 205s 10.1200/JCO.2003.01.068 12743135
7. Prospective on ovarian cancer: why prevent? WJ Hoskins, J Cell Biochem Suppl 1995 23 189 99 10.1002/jcb.240590926 8747396
8. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? SM Crawford J Peace, Ann Oncol 2005 16 47 50 10.1093/annonc/mdi012 15598937
9. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. SM Eisenkop NM Spirtos RL Friedman WC Lin AL Pisani S Perticucci, Gynecol Oncol 2003 90 390 396 10.1016/S0090-8258(03)00278-6 12893206
10. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. WP McGuire WJ Hoskins MF Brady PR Kucera EE Partridge KY Look DL Clarke-Pearson M Davidson, N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563
11. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. RF Ozols BN Bundy BE Greer JM Fowler D Clarke-Pearson RA Burger RS Mannel K DeGeest EM Hartenbach R Baergen, J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02.153 12860964
12. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. P Hoskins E Eisenhauer I Vergote J Dubuc-Lissoir B Fisher R Grimshaw A Oza M Plante G Stuart J Vermorken, J Clin Oncol 2000 18 4038 4044 11118464
13. Screening for ovarian cancer: a pilot randomised controlled trial. IJ Jacobs SJ Skates N MacDonald U Menon AN Rosenthal AP Davies R Woolas AR Jeyarajah K Sibley DG Lowe DH Oram, Lancet 1999 353 1207 1210 10.1016/S0140-6736(98)10261-1 10217079
14. Biomarkers of ovarian tumours. AV Rapkiewicz V Espina EF Petricoin III LA Liotta, Eur J Cancer 2004 40 2604 2612 10.1016/j.ejca.2004.05.021 15541961
15. Tumor markers in the management of patients with ovarian cancer. MK Tuxen G Soletormos P Dombernowsky, Cancer Treat Rev 1995 21 215 245 10.1016/0305-7372(95)90002-0 7656266
16. Abstracts of the first scientific workshop of the Early Detection Research Network. September 2000. Dis Markers 2001 17 3 38 11381202
17. New tumor markers: CA125 and beyond. RC Bast Jr D Badgwell Z Lu R Marquez D Rosen J Liu KA Baggerly EN Atkinson S Skates Z Zhang A Lokshin U Menon I Jacobs K Lu, Int J Gynecol Cancer 2005 15 Suppl 3 274 81 10.1111/j.1525-1438. 2005.00441.x 16343244
18. Role of tumour markers in monitoring epithelial ovarian cancer. T Meyer GJ Rustin, Br J Cancer 2000 82 1535 1538 10.1054/bjoc.2000.1174 10789720
19. Cancer antigen 125 and prognosis. E Hogdall, Curr Opin Obstet Gynecol 2008 20 4 8 10.1097/GCO.0b013e3282f2b124 18196998
20. Reactivity of a monoclonal antibody with human ovarian carcinoma. RC Bast Jr M Feeney H Lazarus LM Nadler RB Colvin RC Knapp, J Clin Invest 1981 68 1331 1337 10.1172/JCI110380 7028788
21. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. RC Bast Jr TL Klug E St John E Jenison JM Niloff H Lazarus RS Berkowitz T Leavitt CT Griffiths L Parker VR Zurawski Jr RC Knapp, N Engl J Med 1983 309 883 887 6310399
22. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. K Nustad RC Bast Jr TJ Brien O Nilsson P Seguin MR Suresh T Saga S Nozawa OP Bormer HW de Bruijn M Nap A Vitali M Gadnell J Clark K Shigemasa B Karlsson FT Kreutz D Jette H Sakahara K Endo E Paus D Warren S Hammarstrom P Kenemans J Hilgers, Tumour Biol 1996 17 196 219 10.1159/000217982 8685601
23. Optimizing primary chemotherapy in ovarian cancer. M Markman, Hematol Oncol Clin North Am 2003 17 957 68 viii 10.1016/S0889-8588(03)00058-3 12959185
24. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. P Kenemans GJ van Kamp P Oehr RA Verstraeten, Clin Chem 1993 39 2509 2513 8252723
25. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. EV Hogdall L Christensen SK Kjaer J Blaakaer A Kjaerbye-Thygesen S Gayther IJ Jacobs CK Hogdall, Gynecol Oncol 2007 104 508 515 10.1016/j.ygyno.2006.09.028 17113137
26. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. GJ Rustin AE Nelstrop MK Tuxen HE Lambert, Ann Oncol 1996 7 361 364 8805927
27. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. GJ Rustin M Marples AE Nelstrop M Mahmoudi T Meyer, J Clin Oncol 2001 19 4054 4057 11600607
28. CA 125: the past and the future. RC Bast Jr FJ Xu YH Yu S Barnhill Z Zhang GB Mills, Int J Biol Markers 1998 13 179 187 10228898
29. Ovarian cancer screening in the general population. U Menon IJ Jacobs, Curr Opin Obstet Gynecol 2001 13 61 64 10.1097/00001703-200102000-00009 11176234
30. CA 125: fundamental and clinical aspects. RH Verheijen S Mensdorff-Pouilly GJ van Kamp P Kenemans, Semin Cancer Biol 1999 9 117 124 10.1006/scbi.1998.0114 10202133
31. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. BW Yin KO Lloyd, J Biol Chem 2001 276 27371 27375 10.1074/jbc.M103554200 11369781
32. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. SJ Skates U Menon N MacDonald AN Rosenthal DH Oram RC Knapp IJ Jacobs, J Clin Oncol 2003 21 206s 210s 10.1200/JCO.2003.02.955 12743136
33. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? V Nossov M Amneus F Su J Lang JM Janco ST Reddy R Farias-Eisner, Am J Obstet Gynecol 2008 199 3 215 23 10.1016/j.ajog.2008.04.009 18468571
34. Prospective study of serum CA-125 levels as markers of ovarian cancer. KJ Helzlsouer TL Bush AJ Alberg KM Bass H Zacur GW Comstock, JAMA 1993 269 1123 1126 10.1001/jama.269.9.1123 8433467
35. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. MJ Duffy JM Bonfrer J Kulpa GJ Rustin G Soletormos GC Torre MK Tuxen M Zwirner, Int J Gynecol Cancer 2005 15 679 691 10.1111/j.1525-1438.2005. 00130.x 16174214
36. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. GJ Rustin RC Bast Jr GJ Kelloff JC Barrett SK Carter PD Nisen CC Sigman DR Parkinson RW Ruddon, Clin Cancer Res 2004 10 3919 3926 10.1158/1078-0432.CCR-03-0787 15173101
37. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. M Markman M Federico PY Liu E Hannigan D Alberts, Gynecol Oncol 2006 103 195 198 10.1016/j.ygyno.2006.02.024 16595148
38. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. JM Riedinger J Wafflart G Ricolleau N Eche H Larbre JP Basuyau I Dalifard K Hacene MF Pichon, Ann Oncol 2006 17 1234 1238 10.1093/annonc/mdl120 16766592
39. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. B Gronlund H Dehn CK Hogdall SA Engelholm M Jorgensen B Norgaard-Pedersen EV Hogdall, Int J Gynecol Cancer 2005 15 836 843 10.1111/j.1525-1438.2005.00145.x 16174233
40. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. A Gadducci P Zola F Landoni T Maggino E Sartori T Bergamino R Cristofani, Gynecol Oncol 1995 58 42 47 10.1006/gyno.1995.1181 7789889
41. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. IG Ron M Inbar I Gelernter O Lewysohn D Ayalon J Dale S Chaitchik, Acta Obstet Gynecol Scand 1994 73 658 662 10.3109/ 00016349409013462 7941993
42. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. NG Davidson S Khanna PH Kirwan D Bircumshaw, Clin Oncol (R Coll Radiol) 1991 3 32 36 2001340
43. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. GJ Rustin JN Gennings AE Nelstrop H Covarrubias HE Lambert KD Bagshawe, J Clin Oncol 1989 7 1667 1671 2681555
44. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. ME van der Burg FB Lammes WL van Putten G Stoter, Gynecol Oncol 1988 30 307 312 10.1016/0090-8258(88)90244-2 3164697
45. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. HS Kim NH Park HH Chung JW Kim YS Song SB Kang, Onkologie 2008 31 315 320 10.1159/000131270 18547972
46. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. MM Juretzka RR Barakat DS Chi A Iasonos J Dupont NR Abu-Rustum EA Poynor C Aghajanian D Spriggs ML Hensley P Sabbatini, Gynecol Oncol 2007 104 176 180 10.1016/j.ygyno.2006.07. 027 16996584
47. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. JM Riedinger F Bonnetain JP Basuyau N Eche H Larbre I Dalifard J Wafflart G Ricolleau MF Pichon, Ann Oncol 2007 18 881 885 10.1093/annonc/mdl500 17301071
48. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. F Badulescu A Badulescu M Schenker CF Popescu Z Stoica, Rom J Morphol Embryol 2005 46 329 334 16688372
49. The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. J Fisken RC Leonard M Stewart GJ Beattie C Sturgeon L Aspinall JE Roulston, Br J Cancer 1993 68 140 145 8318405
50. Early serum CA125 response and outcome in epithelial ovarian cancer. CW Redman GR Blackledge K Kelly J Powell EJ Buxton DM Luesley, Eur J Cancer 1990 26 593 596 10.1016/0277-5379(90)90085-8 2144746
51. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. S Colakovic V Lukic L Mitrovic S Jelic S Susnjar J Marinkovic, Int J Biol Markers 2000 15 147 152 10883888
52. CA 125 half-life in ovarian cancer: a multivariate survival analysis. CA Yedema P Kenemans F Voorhorst G Bon C Schijf L Beex A Verstraeten J Hilgers J Vermorken, Br J Cancer 1993 67 1361 1367 8512822
53. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. N Osman N O'Leary E Mulcahy N Barrett F Wallis K Hickey R Gupta, Ir Med J 2008 101 245 247 18990955
54. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. AL Petri E Hogdall IJ Christensen SK Kjaer J Blaakaer CK Hogdall, APMIS 2006 114 359 363 10.1111/j.1600-0463.2006.apm-397.x 16725012
55. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. BC Cooper AK Sood CS Davis JM Ritchie JI Sorosky B Anderson RE Buller, Obstet Gynecol 2002 100 59 64 10.1016/S0029-7844(02)02057-4 12100804
56. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. RE Buller S Vasilev PJ DiSaia, Am J Obstet Gynecol 1996 174 1241 1253 10.1016/S0002-9378(96)70667-1 8623852
57. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. JP Geisler GA Miller TH Lee RM Harwood MC Wiemann HE Geisler, J Reprod Med 1996 41 140 142 8778409
58. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. F Nagele E Petru M Medl C Kainz AH Graf P Sevelda, Obstet Gynecol 1995 86 259 264 10.1016/0029-7844(95)00126-C 7617357
59. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. AP Makar GB Kristensen J Kaern OP Bormer VM Abeler CG Trope, Obstet Gynecol 1992 79 1002 1010 1579296
60. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. P Sevelda M Schemper J Spona, Am J Obstet Gynecol 1989 161 1213 1216 2589442
61. KRCGWHCHKH: Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. V Moebus, J Tumor Marker Oncol 1988 3 251 258
62. The clinical significance of pre-operative serum CA 125 in ovarian cancer. DJ Cruickshank WT Fullerton A Klopper, Br J Obstet Gynaecol 1987 94 692 695 2441738
63. Serum CA 125 levels and survival in advanced ovarian cancer. K Munstedt M Krisch S Sachsse H Vahrson, Arch Gynecol Obstet 1997 259 117 123 10.1007/BF02505319 9187463
64. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. JM Riedinger N Eche JP Basuyau I Dalifard K Hacene MF Pichon, Gynecol Oncol 2008 109 194 198 10.1016/j.ygyno.2008.01.035 18329083
65. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. A Gadducci S Cosio A Fanucchi S Negri R Cristofani AR Genazzani, Gynecol Oncol 2004 93 131 136 10.1016/j.ygyno.2003.12.043 15047226
66. Prognostic indicators for poor risk epithelial ovarian carcinoma. M Rosman CL Hayden RP Thiel JT Chambers EI Kohorn SK Chambers PE Schwartz, Cancer 1994 74 1323 1328 10.1002/1097-0142(19940815)74:4<1323::AID-CNCR28207404233. 0.CO;2-5 8055455
67. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. T Hogberg B Kagedal, Acta Obstet Gynecol Scand 1990 69 423 429 10.3109/00016349009013306 2270768
68. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. VJ Hunter L Daly M Helms JT Soper A Berchuck DL Clarke-Pearson RC Bast Jr, Am J Obstet Gynecol 1990 163 1164 1167 2171337
69. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. RE Hawkins K Roberts E Wiltshaw J Mundy IJ Fryatt VR McCready, Br J Obstet Gynaecol 1989 96 1395 1399 2620051
70. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. GB Gard CR Houghton, Gynecol Oncol 1994 53 283 289 10.1006/gyno.1994.1135 8206399
71. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant. G Frasci S Conforti F Zullo P Mastrantonio G Comella P Comella G Persico RV Iaffaioli, Cancer 1996 77 1122 1130 10.1002/(SICI)1097-0142(19960315)77:6<1122::AID-CNCR183.0.CO;2-3 8635133
72. CA-125 AUC as a predictor for epithelial ovarian cancer relapse. A Mano A Falcao I Godinho J Santos F Leitao C de Oliveira M Caramona, Cancer Biomark 2008 4 73 81 18503158
73. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. A Mano A Falcao I Godinho J Santos F Leitao C Oliveira M Caramona, Gynecol Oncol 2005 97 529 534 10.1016/j.ygyno.2005.01.040 15863156
74. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. T Riman I Persson S Nilsson, Clin Endocrinol (Oxf) 1998 49 695 707 10.1046/j.1365-2265.1998.00577.x 10209555
75. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. TJ O'Brien JB Beard LJ Underwood RA Dennis AD Santin L York, Tumour Biol 2001 22 348 366 10.1159/000050638 11786729
76. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. RA Burger KM Darcy PJ DiSaia BJ Monk EA Grosen T Gatanaga GA Granger J Wang C Tian P Hanjani DE Cohn, Cancer 2004 101 106 115 10.1002/cncr.20314 15221995
77. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. MK Tuxen G Soletormos P Dombernowsky, Br J Cancer 2001 84 1301 1307 10.1054/bjoc.2001.1787 11355938
78. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. JM Bidart F Thuillier C Augereau J Chalas A Daver N Jacob F Labrousse H Voitot, Clin Chem 1999 45 1695 1707 10508114
79. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. C Peters-Engl A Obermair H Heinzl P Buxbaum P Sevelda M Medl, Br J Cancer 1999 81 662 666 10.1038/sj.bjc.6690744 10574252
80. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. A Gadducci S Cosio R Tana AR Genazzani, Crit Rev Oncol Hematol 2009 69 1 12 27 10.1016/j.critrevonc.2008.05.001 18595727